AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Electrochemical Detection of Human Cytochrome P450 2A6 Inhibition: A Step toward Reducing Dependence on Smoking

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/149936> since

Published version:

DOI:10.1021/ac4041839

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

Castrignanò S, Ortolani A, Sadeghi SJ, Di Nardo G, Allegra P, and Gilardi G. Electrochemical detection of human cytochrome P450 2A6 inhibition: a step toward reducing dependence on smoking. Anal.Chem. (2014) 86, 2760-2766. doi: 10.1021/ac4041839

The definitive version is available at:

La versione definitiva è disponibile alla URL:

<http://pubs.acs.org/doi/abs/10.1021/ac4041839>

Electrochemical detection of human Cytochrome P450 2A6 inhibition: a step towards reducing dependence from smoking

*Silvia Castrignano¹, Alex Ortolani¹, Sheila J. Sadeghi^{1,2}, Giovanna Di Nardo¹, Paola Allegra¹ and
Gianfranco Gilardi^{1,2*}*

¹Department of Life Sciences and Systems Biology, University of Torino, 10123 Torino, Italy

²Centre for Nanostructured Interfaces and Surfaces, University of Torino, via Pietro Giuria 7,
10125 Torino, Italy.

KEYWORDS: Cytochrome P450; 2A6; Glassy carbon; Protein immobilisation; FTIR; PDDA

ABSTRACT

Inhibition of human cytochrome P450 2A6 has been demonstrated to play an important role in nicotine metabolism and consequent smoking habits.

Here the “Molecular Lego” approach was used to achieve the first reported electrochemical signal of human CYP2A6 and to improve its catalytic efficiency on electrode surfaces. The enzyme was fused at the genetic level to flavodoxin from *Desulfovibrio vulgaris*(FLD) to create the chimeric CYP2A6-FLD. Electrochemical characterization by cyclic voltammetry shows clearly defined redox transitions of the haem domain in both CYP2A6 and CYP2A6-FLD. Electrocatalysis experiments using coumarin as substrate followed by fluorimetric quantification of the product were performed with immobilised CYP2A6 and CYP2A6-FLD. Comparison of the kinetic parameters showed that coumarin catalysis was carried out with a higher efficiency by the immobilised CYP2A6-FLD, with a calculated k_{cat} value significantly higher ($P < 0.005$) than that of CYP2A6, while the affinity for the substrate (K_M) remained unaltered. The chimeric system was also successfully used to demonstrate the inhibition of the electrochemical activity of the immobilised CYP2A6-FLD, towards both coumarin and nicotine substrates, by tranylcypromine, a potent and selective CYP2A6 inhibitor.

This work shows that CYP2A6 turnover efficiency is improved when the protein is linked to FLD redox module and this strategy can be utilized for the development of new clinically relevant biotechnological approaches suitable for deciphering the metabolic implications of CYP2A6 polymorphism and for the screening of CYP2A6 substrates and inhibitors.

INTRODUCTION

Human cytochrome P450 2A6 (CYP2A6) is a polymorphic Phase I drug metabolising enzyme representing up to 10% of total CYPs present in the liver where it is mainly expressed.¹ There is considerable interest in CYP2A6 primarily due to its leading role in human metabolism of nicotine, the addictive agent present in tobacco. About 80 % of nicotine is metabolized by CYP2A6, and a clear relationship between CYP2A6 polymorphism and dependence from smoking has been demonstrated, together with the consequent risk of lung cancer.^{2,3} It has been widely reported that the individual variability in nicotine metabolism rate, including ethnic group and gender related differences, is highly correlated to CYP2A6 genetic polymorphism.² In particular, it has been observed that subjects with a genetic basis for slow CYP2A6 metabolism smoke fewer cigarettes and are more likely to stop smoking, compared to individuals with faster metabolism.^{2,3} For these reasons, the use of CYP2A6 inhibitors has been suggested as a possible treatment strategy for tobacco-dependent smokers.⁴ Specifically, CYP2A6 inhibition has been proposed for the prevention and treatment of tobacco dependence, to facilitate pharmacological approaches such as nicotine replacement therapy by promoting exposure reduction, enhancing treatment efficacy, and reducing the susceptibility to carcinogens.⁴

Amongst drugs and xenobiotics that can be suitable for CYP2A6 inhibition, methoxsalen, a clinically approved drug for the treatment of psoriasis, has been proposed to reduce smoking behaviour⁵ but it may not be selective for CYP2A6 and the risk of undesirable drug-drug interactions may be relevant. As a natural remedy, also grapefruit juice, whose inhibitory characteristic of CYPs is well established, has been proposed in a clinical study.⁶ Other attempts have also been made by producing synthetic CYP2A6 inhibitors by mimicking the chemical

structure of nicotine.⁷ The discovery and improvement of new powerful and selective CYP2A6 inhibitors with low or no risk of undesirable side effects is an ongoing research area. Therefore the development of new bioanalytical methods suitable for the screening of CYP2A6 substrates and inhibitors together with metabolic implications of CYP2A6 polymorphism is extremely desirable and of high clinical relevance: this is the aim of the present work.

A well known substrate of CYP2A6 is coumarin. In humans around 80% of coumarin is metabolised by CYP2A6 and its 7-hydroxylation is commonly used both *in vitro* and *in vivo* as a probe of CYP2A6 activity.¹ Coumarins belong to the wide class of plant-derivative benzopyrones and are the simplest member of this chemical family of compounds. Medical importance of coumarin derivatives is related to their wide function multiplicity that can be translated to high pharmacological potential.⁸ Firstly, coumarin derivatives are extensively used as anti-coagulant and anti-thrombotic agents.^{9,10} Coumarin can also act as anti-inflammatory and anti-oxidant agent¹¹ as well as anti-bacterial and anti-viral agent.⁸ In addition, coumarin has been shown to have neuroprotective capabilities against neurodegenerative disorders such as Alzheimer's and Parkinson's diseases through the inhibition of acetylcholinesterase activity.^{12,13} They also have pronounced anti-HIV activity and have been proposed in combination with other anti-HIV drugs for therapeutic purposes.¹⁴ Lastly, a number of natural and synthetic coumarins have been shown to have clinically relevant anticancer activities.⁸

Owing to their biotechnological potential and relevance to drug metabolism, CYPs have received considerable attention for the development of bio-electrochemical platforms suitable for substrate and inhibitor screening.¹⁵⁻²⁴

Particular interest has been focused on the improvement of the electronic coupling of the enzyme with the electrode surface and of its catalytic efficiency. In a fully coupled system

reducing equivalents and molecular oxygen consumed are stoichiometrically equivalent to the product formed. In uncoupled systems, reducing equivalents and molecular oxygen are not used exclusively for product formation leading to the production of superoxide and hydrogen peroxide by-products and resulting in an impairment of the enzyme catalytic activity.²⁰

In order to address the difficulties, significant improvement has been achieved by optimising advanced methods for electrode surface modification in conjunction with the development of appropriate protein engineering strategies.^{20,21,23} To this end, our group has previously developed and implemented the so-called “molecular Lego” approach²⁵⁻²⁹ based on the genetic fusion of electron transfer modules such as *Desulfovibrio vulgaris* flavodoxin (FLD) to the CYP of interest resulting in active multi-domain P450 enzymes. In particular, it has been demonstrated that using artificial redox chains it is possible to regulate the electron flow from the electrode to the catalytic domain by mediation of the artificial reductase domain thus enhancing coupling efficiency and catalytic activity.^{20,30}

Here we apply the “molecular Lego” approach to improve the catalytic efficiency of CYP2A6 by fusing it, at the genetic level, with FLD redox module, chosen for its high sequence similarity to the FMN binding domain of the class II CYP reductases.²⁵ Electrochemical study of CYP2A6-FLD is performed by immobilising the fusion protein on poly-diallyldimethylammonium chloride (PDDA) modified glassy carbon electrode and results obtained are compared to those relative to CYP2A6 enzyme as a control. The rate of electron flow through CYP2A6-FLD redox chain is also estimated by applying Laviron’s theory³¹ using cyclic voltammetry. Furthermore, the catalytic performance of CYP2A6-FLD is investigated using the well known substrate coumarin. We examine CYP2A6-FLD turnover efficiency in the presence of coumarin by chronoamperometric electrocatalysis on the glassy carbon immobilised enzyme in comparison to

CYP2A6. In addition, coupling efficiency of the enzyme is examined during coumarin electrocatalysis by on-line measurement of hydrogen peroxide formed using screen-printed platinum electrode. Finally, the inhibition of immobilised CYP2A6-FLD in the presence of tranilcypromine, a potent and selective CYP2A6 inhibitor is demonstrated towards coumarin and nicotine electrocatalysis.

EXPERIMENTAL SECTION

Chemicals. Analytical grade chemicals were used with no further purification. All solutions were prepared with ultra pure deionised water. Coumarin, 7-hydroxy-coumarin, nicotine, tranylcypromine (Sigma-Aldrich) and nicotine- $\Delta 1'(5')$ -iminium diperchlorate salt (Biozol) solutions were prepared just before use by dissolving the adequate amount in the appropriate solvent. Poly-diallyldimethylammonium chloride (PDDA) (Sigma-Aldrich) was used without dilution.

Engineering, expression and purification of CYP2A6 and CYP2A6-FLD. Cyp2A6 gene was modified at the 5'-end, corresponding to the N-terminal of the protein, in order to remove the hydrophobic membrane anchor by deleting the first 22 aminoacids using the primer 2A6 FW reported below. This was done with the aim of improving the expression and stability of the construct, as previously reported.³² The cyp2A6 gene was amplified by PCR using the forward and reverse primers (restriction enzyme sites shown in bold) and subsequently ligated into the pCW expression vector.

2A6 FW

5'CAA GAT ACT ACC CAT ATG GCG AAA AAG ACC TCG AGC AAG GGG AAG CTG
3'

2A6 RV

5' TTC CTG CCC CGC CAC CAT CAC CAT TGA AAG CTT GCG AGG GCT 3'

Cyp2A6-FLD was cloned into pCW expression vector starting from CYP2A6 clone. Two primers, reported below, were used to amplify and modify the existing Cyp2A6 in order to delete the stop codon and to insert a unique AvrII restriction site. The AvrII restriction site allowed for

the cloning of the modified Cyp2A6 gene into the pCW expression vector already containing the sequence coding for the FLD gene.^{27,28}

2A6 FW

5'CAA GAT ACT ACC CAT ATG GCG AAA AAG ACC TCG AGC AAG GGG AAG CTG
3'

2A6 RV

5' CCA CGA AAC TAC ACC ATG AGC TTC CTG CCC CGC CCT AGG AAT TAA 3'

Both clones were sequenced in order to confirm the correct amino acid sequence. As previously reported^{27,28} CYP2A6 and CYP2A6-FLD fusion proteins were expressed in *E. coli* DH5 α cells with a six histidine tag at the C-terminus. The resulting recombinant proteins were purified by coupling ionic exchange (DEAE fast flow) and Ni-affinity chromatography. Both CYP2A6 and CYP2A6-FLD were stored in 50 mM phosphate buffer pH 7.4 with 20% glycerol at -20°C.

Fourier transform infrared spectroscopy (FTIR). Infrared spectra of CYP2A6 were acquired using attenuated total reflectance (ATR) tool (Harrick Scientific Products, USA). Protein samples were prepared on gold-PET flat surface substrates following the same procedure described for glassy carbon electrodes and compared with samples prepared by gently mixing equal volumes of enzyme solution and buffer (50 mM phosphate buffer pH 7.4 with 20% glycerol). Before the FTIR analysis, samples were kept overnight at 4°C. All spectra were collected from 4000 to 800 cm⁻¹ using a Bruker Model Tensor 27 FT-IR spectrometer (Bruker Instruments, USA) with a scan velocity of 10 kHz and a resolution of 4 cm⁻¹.³³ During data acquisition, the spectrometer was continuously purged with nitrogen at room temperature. Data were collected in triplicates and spectra were averaged using the Opus software (Bruker

Instruments, USA). Spectra of the protein were collected in triplicate, subsequently averaged and then corrected by subtraction of control samples acquired under the same scanning and temperature conditions. In particular, IR spectra of buffer or PDDA, were used with the same dilution as background for enzyme samples.

Immobilisation on glassy carbon electrodes. Both CYP2A6 and CYP2A6-FLD proteins were immobilised on PDDA modified glassy carbon electrodes (diameter of 0.07 cm²- BASi, UK). To this end, a 1:1 mixture of PDDA: protein was cast onto clean glassy carbon electrodes and allowed to set overnight at 4 °C.

Cyclic voltammetry and chronoamperometry. All electrochemical experiments were carried out at room temperature (25 °C) and in 50 mM phosphate buffer pH 7.4, containing 100 mM KCl as supporting electrolyte, using an Autolab PGSTAT12 potentiostat (Ecochemie, The Netherlands) controlled by GPES3 software. A conventional three-electrode glass cell, equipped with a platinum wire counter electrode, an Ag/AgCl (3 M NaCl) reference electrode and 3 mm diameter glassy carbon working electrode (BASi, UK), was also used.

Electrochemical investigation of CYP2A6 and CYP2A6-FLD properties was performed by cyclic voltammetry and the potential was scanned between 400 and -850 mV at a scan rate of 120 mV/sec. Cyclic voltammetry experiments were performed in a nitrogen atmosphere within a glovebox (Belle Technologies, UK).

Electrochemically driven substrate catalysis by CYP2A6 and CYP2A6-FLD was performed using chronoamperometry with an applied potential bias of -650 mV for 30 min. In order to assure the substrate permeation into the enzymatic layer and minimize mass transport influence at the transducer surface, both CYP2A6 and CYP2A6-FLD were immobilised through PDDA on glassy carbon rotating disk electrodes. All chronoamperometric electrocatalysis experiments

were performed at 200 rpm rotation speed using a BASi RDE-2 rotator system (Bioanalytical Systems Inc., USA). Chronoamperometric procedure was applied on freshly prepared electrodes in the presence of increasing concentrations of substrate and the product obtained after the 30 min reaction was immediately quantified by fluorescence spectroscopy detection in the case of coumarin and by high performance liquid chromatography (HPLC) in the case of nicotine.

The coupling efficiency of the immobilised enzymes was measured during the electrocatalysis of coumarin (saturating concentration = 10 μM) using the above-mentioned procedure. In particular, the amount of hydrogen peroxide produced was estimated using miniaturised screen-printed platinum electrodes (BVT Technologies, Czech Republic) by sampling, every 5 min, 30 μL of the electrocatalysis solution. Hydrogen peroxide quantification was performed on platinum screen-printed electrode, after calibration with standard solutions, in chronoamperometry by applying a potential of 600 mV for 5 min and by measuring the steady state current. Hydrogen peroxide concentration was estimated using the calibration curve after volume appropriate correction. As a control experiment, ethanol (used for dissolving coumarin) was added instead of the substrate to both CYP2A6 and CYP2A6-FLD electrodes.

Inhibition studies were carried out on CYP2A6-FLD glassy carbon electrodes using chronoamperometry, with the same parameters mentioned above for coumarin and nicotine electrocatalysis. Inhibition experiments were performed in the presence of coumarin (10 μM) or nicotine (150 μM) as the substrate and increasing concentrations of tranlycypromine (from 0.01 to 100 μM) as the inhibitor. The decrease in the amount of 7-hydroxy coumarin formed in the presence of the tranlycypromine inhibitor during coumarin electrocatalysis, was calculated by fluorescence spectroscopy. The decrease in the amount of nicotine- $\Delta 1'(5')$ -iminium ion formed

in the presence of the tranlycypromine inhibitor during nicotine electrocatalysis, was estimated by HPLC.

Fluorescence spectroscopy. Following the termination of the chronoamperometric experiments in the presence of different concentrations of the substrate coumarin, the electrochemical cell contents were transferred to a fluorimeter for the subsequent 7-hydroxy coumarin product quantification. Fluorescence spectra were recorded at room temperature with a Perkin Elmer LS 55 fluorescence spectrometer (Perkin Elmer, USA). Excitation wavelength was set at 325 nm and emission was monitored between 400 nm and 600 nm with a detected maximum emission at 450 nm. Excitation and emission slits size were set at 4 nm and 6 nm, respectively.

HPLC. The quantification of nicotine electrocatalysis product formation was achieved by HPLC coupled with a diode array UV detector (Agilent-1200, Agilent technologies, USA) equipped with a 4.6 x 150 mm 5 μ m Eclipse XDB-C18 column. For this purpose, standard solutions of nicotine and $\Delta 1'(5')$ -iminium ion were separated using a linear gradient elution programmed as follows: linear gradient elution from 20% to 50% acetonitrile and 80% to 50 % 20 mM phosphate buffer pH 7, 0-10 min; isocratic elution of 50% acetonitrile and 50% 20 mM phosphate buffer pH 7, 10-24 min; linear gradient elution to 20% acetonitrile and 80% 20 mM phosphate buffer pH 7, 24 min-end of the run. Flow rate was set to 1 mL/min. Detection wavelength was set to 257 nm. Retention times were 3 min and 21 min for $\Delta 1'(5')$ -iminium ion and nicotine, respectively.

RESULTS AND DISCUSSION

CYP2A6 and CYP2A6-FLD were expressed in *E. coli* and purified using the protocols established in our lab for other CYPs and reported previously.²⁷ Reduction of the haem followed by bubbling of carbon monoxide in both purified proteins showed a complete spectral shift of the Soret peak at 418 nm to the expected 450 nm, indicating the presence of an active enzyme.

Prior to the electrochemical experiments ATR-FTIR analysis was carried out to assess the structural integrity of the catalytic domain in the presence and in the absence of the cationic polyelectrolyte PDPA (Poly-diallyldimethylammonium chloride). In particular, the spectral region included between 1450 and 1750 cm^{-1} was considered, containing information on protein secondary structure composition. As shown in Figure 1, spectra obtained for both CYP2A6 in the absence and in the presence of PDPA are essentially similar and exhibit the amide I and II bands, which are characteristics of secondary structure of proteins.³⁴ Amide I band ($\sim 1650 \text{ cm}^{-1}$) consists of a group of overlapped signals, mainly due to the peptidic carbonyl group stretching mode with a minor contribution from the out-of-phase C-N stretching vibration.³⁴ Grouped bands centred at around 1550 cm^{-1} are commonly assigned to the amide II band, which corresponds to the out-of-phase combination of the peptidic N-H in plane bend and the C-N stretching vibration. Additionally, the peak at 1517 cm^{-1} can be assigned to the C-C stretch and C-H bend of side chain tyrosine residues.³⁴ Moreover, a set of bands that can be assigned to the amide III mode is well detectable in the region between 1200 and 1400 cm^{-1} , these signals are related to the in-phase combination of the peptidic N-H and C-N bonds bending vibration.³⁴

Figure 1. FTIR spectra of A) CYP2A6, B) CYP2A6 in the presence of PDDA. Spectra were collected in triplicates and subsequently averaged and corrected by background subtraction.

The ATR-FTIR data shows that the catalytic domain is not denatured upon immobilisation and that the secondary structure of CYP2A6 is not affected by the presence of PDDA. Subsequently, direct electrochemistry of both enzymes was performed using cyclic voltammetry on PDDA modified glassy carbon electrodes. Cyclic voltammograms of CYP2A6 and CYP2A6-FLD collected under anaerobic conditions are reported in the Figure 2 where a redox couple corresponding to haem $\text{Fe}^{\text{III/II}}$ transition having a midpoint potential of about -230 mV is shown.

Figure 2. Anaerobic cyclic voltammograms of CYP2A6 (A) and CYP2A6-FLD (B) on PDDA glassy carbon electrodes. Shown are the original and baseline corrected (upper traces) cyclic voltammograms. Scan rate: 120 mV s^{-1} in 50 mM potassium phosphate pH 7.4 with 100 mM KCl at 25°C .

An additional redox couple is observed in the cyclic voltammogram of CYP2A6-FLD and is assigned to the semiquinone–hydroquinone transition of the FMN cofactor with a midpoint potential of about -660 mV. No voltammetric peaks are observed in the absence of enzyme (data not shown). Peak-to-peak separation of about 130 mV for the haem $\text{Fe}^{\text{III/II}}$ transition and 180 mV for the FLD semiquinone-hydroquinone indicate a quasi-reversible electrochemical processes typical of slow electron transfer kinetics. The electron transfer rate constant (k_s) was also calculated from empirically fitted Laviron's equations.³¹ In particular, irreversible electrochemistry of both CYP2A6 and CYP2A6-FLD PDDA immobilised proteins was studied in cyclic voltammetry by increasing the scan rate from 0.2 to 0.5 V s⁻¹ and the cathodic and anodic peak potentials were plotted versus the logarithm of the scan rate. The k_s values were calculated from the intercept of the E plot versus $\ln v$ and were determined to be 0.13 s⁻¹ for CYP2A6 and 0.08 s⁻¹ for CYP2A6-FLD. As previously reported,²³ low electron transfer rate is essential for electrochemically-driven catalysis of P450 systems because it allows for the fine tuning of the electron delivery from the reductase to the haem catalytic site. A summary of electrochemical data calculated for CYP2A6 and CYP2A6-FLD is reported in Table 1.

Table 1: Redox properties of CYP2A6 and CYP2A6-FLD immobilised on glassy carbon electrodes modified with PDDA.

	E_c (mV)	E_a (mV)	E_m (mV)	ΔE (mV)	k_s (s ⁻¹)
CYP2A6	-294 ± 8	-174 ± 2	-234 ± 5	121 ± 7	0.13
CYP2A6- FLD	-321 ± 12	-128 ± 4	-225 ± 4	134 ± 15	0.08
	-753 ± 7	-572 ± 6	-662 ± 6	181 ± 10	

The activity of both CYP2A6 and CYP2A6-FLD using coumarin as the marker substrate was investigated by chronoamperometric delivery of reducing equivalents to the immobilised enzymes in the presence of increasing concentrations of this substrate. Fluorescence detection was then used to quantify the 7-hydroxy coumarin product³⁵ with an excitation wavelength of 325 nm and an emission wavelength of 463 nm as described in the Methods section. The results obtained using CYP2A6 and CYP2A6-FLD glassy carbon electrodes in the presence of increasing concentrations of coumarin are shown in Figure 3A and 3B, respectively. Michaelis-Menten curves for the turnover of both CYP2A6 and CYP2A6-FLD in the presence of coumarin were obtained by plotting the rate of product formation versus the relative coumarin concentrations (Figure 3C). As can be seen from the figure, a significant difference between CYP2A6 and CYP2A6-FLD was observed in the presence of coumarin, also confirmed by one-way ANOVA followed by post hoc Tukey test ($P < 0.001$). K_M and k_{cat} values for the electrocatalysis of coumarin were calculated to be $1.03 \pm 0.05 \mu\text{M}$ and $0.17 \pm 0.01 \text{ min}^{-1}$ for CYP2A6 and $1.00 \pm 0.28 \mu\text{M}$ and $0.28 \pm 0.01 \text{ min}^{-1}$ for CYP2A6-FLD. Performing student's t-test, no differences were found when evaluating K_M values, whereas a significant difference between CYP2A6 and CYP2A6-FLD was found when comparing k_{cat} values. In particular, the k_{cat} value of coumarin electrocatalysis was significantly higher for CYP2A6-FLD than for CYP2A6 ($P < 0.005$).

Figure 3. Formation of 7-hydroxycoumarin by CYP2A6 (A) and CYP2A6-FLD (B) immobilised on PDDA glassy carbon electrodes detected by fluorescence spectroscopy. C) Plot of reaction velocity versus substrate concentration fitted to Michaelis-Menten equation for CYP2A6 (circles) and CYP2A6-FLD (triangles). Data are shown as mean $\pm$ SD of three different electrodes.

Kinetic values obtained for CYP2A6 have been compared in Table 2 with previously published results for coumarin catalysis.³⁶⁻³⁹ Since to our knowledge this is the first report of the immobilisation of CYP2A6, the values reported in the latter table are those of the recombinant enzyme free in solution and not immobilised. Regarding the K_M values, our results were found to be in the same range as those of literature (1-2 μ M), confirming the preservation of protein affinity for the substrate. However, the electrochemical k_{cat} values for both proteins were found to be lower than the values reported for CYP2A6 free in solution. It must be noted that in general the non-oriented immobilisation of enzymes on electrodes does affect the turnover number since not all the enzymes are within distances that allow for electron transfer and this is not unique to the system described here. More interesting though is the comparison between the two immobilised proteins where the chimeric enzyme shows a higher catalytic efficiency (k_{cat}/K_M) to that of the CYP2A6 i.e. 0.28 versus 0.17 min⁻¹ μ M⁻¹.

Table 2: Comparison of calculated kinetic parameters for coumarin catalysis by immobilised CYP2A6 and literature data determined on recombinant enzyme (Rec.) free in solution.

	K_M (μM)	k_{cat} (min^{-1})	Variant, Host
Present work:			
2A6	1.03 ± 0.05	0.17 ± 0.01	Rec., <i>E. Coli</i>
2A6-FLD	1.00 ± 0.28	0.28 ± 0.01	
Soucek, 1999 [36]	1.48 ± 0.37	3.36 ± 0.18	Rec., <i>E. Coli</i>
He et al., 2004 [37]	2.17 ± 0.63	3.23	Rec., <i>Spodoptera frugiperda</i>
Fukami et al., 2005 [38]	1.00 ± 0.10	5.2 ± 0.3	Rec., <i>E. Coli</i>
Yun et al., 2005 [39]	1.80 ± 0.70	4.5 ± 0.5	Rec., <i>E. Coli</i>

An evaluation of the coupling efficiency of immobilised CYP2A6 and CYP2A6-FLD was also carried out by measuring the hydrogen peroxide production during coumarin electrocatalysis. The chronoamperograms of sampled solutions during electrocatalysis of CYP2A6 and CYP2A6-FLD obtained using screen-printed platinum electrodes are shown in Figure 4 (A and B). Hydrogen peroxide production profiles (Figure 4C) were obtained by plotting the calculated hydrogen peroxide concentration values versus time for both coumarin electrocatalysis and control experiments (in the presence of only ethanol- coumarin solvent). The different hydrogen peroxide production profiles were compared by two way ANOVA followed by post hoc Tukey test which showed that hydrogen peroxide produced during coumarin electrocatalysis was significantly higher for immobilised CYP2A6 than CYP2A6-FLD ($P < 0.001$). Furthermore, on CYP2A6 glassy carbon electrodes hydrogen peroxide was produced in statistically higher amounts during coumarin electrocatalysis than during control experiments in the presence of

only buffer ($P < 0.001$). However, no significant differences were found when comparing hydrogen peroxide production during coumarin electrocatalysis and control experiments on CYP2A6-FLD glassy carbon electrodes confirming that the chimeric protein is more coupled. The latter observation is also supported by the fact that the immobilised CYP2A6-FLD yields double the amount of 7-hydroxycoumarin product when compared to CYP2A6 alone, as mentioned earlier (Table 2).

Figure 4. Estimation of the amount of hydrogen peroxide produced during coumarin electrocatalysis by CYP2A6 (A) and CYP2A6-FLD (B) performed on screen-printed platinum electrode. C) Hydrogen peroxide production profile during coumarin electrocatalysis (filled symbols) and control experiments (empty symbols) on immobilised CYP2A6 (circles) and CYP2A6-FLD (triangles) on glassy carbon electrodes.

The data obtained demonstrate that the regulation of electron flow to the haem of immobilised CYP2A6 when genetically fused to *D. vulgaris* FLD significantly enhanced both coupling and catalytic efficiencies of this enzyme towards coumarin hydroxylation.

Finally, the improved catalytic efficiency of CYP2A6 when genetically fused to FLD was examined toward enzyme inhibition in the presence of tranlylcypromine, a potent and relatively

selective inhibitor of CYP2A6.¹ Tranylcypromine is a non hydrazine monoamine oxidase inhibitor used in psychiatry⁴⁰ and has proven inhibitory activity towards many CYPs.¹ Previously published studies on human liver microsomes or cDNA expressing microsomes have reported the inhibition of CYP2A6 activity towards coumarin 7-hydroxylation by tranylcypromine, with calculated K_i values ranging from 0.04 to 0.42 μM .^{1,40,41} Here we used CYP2A6-FLD glassy carbon electrodes to investigate the inhibition of coumarin metabolism by tranylcypromine.

Figure 5. Tranylcypromine concentration-dependent inhibition of coumarin 7-hydroxylation by CYP2A6-FLD modified glassy carbon electrodes. Data are shown as mean $\pm$ SD of three different electrodes.

The inhibition profile of CYP2A6-FLD coumarin 7-hydroxylation by tranylcypromine is shown in Figure 5. The calculated IC_{50} value was $3.1 \pm 0.6 \mu\text{M}$. Using Cheng and Prusoff relationship for competitive inhibition,⁴² the calculated IC_{50} value was also converted to K_i obtaining a value of $0.29 \pm 0.06 \mu\text{M}$ which is in good agreement with previously published results using microsomes.^{1,40,41}

In addition, inhibition experiments in the presence of tranylcypromine were also performed using nicotine as substrate. In humans, about 70 to 80% of nicotine is converted to cotinine in two enzymatic steps. The first is nicotine 5'-oxidation mediated by CYP2A6. Secondly, $\Delta 1'(5')$ -iminium ion product of this reaction is further metabolised to cotinine by aldehyde oxidase.^{6,43,44} Here we firstly calculated K_M value by performing electrocatalysis of nicotine on CYP2A6-FLD glassy carbon electrodes. The estimated K_M value was $131.4 \pm 52.2 \mu\text{M}$, in agreement with previously published results on microsomal CYP2A6 protein [44]. Then we used CYP2A6-FLD glassy carbon electrodes to investigate the inhibition of nicotine metabolism by tranylcypromine. The inhibition profile of CYP2A6-FLD nicotine 5'- oxidation by tranylcypromine is shown in Figure 6.

Figure 6. Tranylcypromine concentration-dependent inhibition of nicotine 5'-oxidation by CYP2A6-FLD modified glassy carbon electrodes. Data are shown as mean $\pm$ SD of three different electrodes.

The calculated IC_{50} value was $3.7 \pm 0.2 \mu M$. Using Cheng and Prusoff relationship for competitive inhibition,⁴² the calculated IC_{50} value was also converted to K_i obtaining a value of $1.72 \pm 0.09 \mu M$. No available literature data about tranilcypromine inhibition of CYP2A6 5'-oxidation of nicotine were found for the comparison of our results.

CONCLUSIONS

In conclusion, for the first time a bio-electrochemical set up suitable for the investigation of CYP2A6 catalytic activity has been developed by immobilising on glassy carbon electrodes the chimeric form of the enzyme CYP2A6-FLD obtained by genetically fusing CYP2A6 with FLD. The fusion protein showed an improved catalytic efficiency in agreement with what has been previously reported for CYP3A4²⁰ where the regulation of the electron flow to the haem through FLD resulted in an increase of product formation due to an enhancement of the coupling efficiency. It was also demonstrated that the increase in catalytic activity observed for CYP2A6-FLD when compared to CYP2A6 could be related to the improved control of the enzyme coupling efficiency and to a more refined electron flow tuning. The CYP2A6 based bio-electrochemical platform was also successfully used to test enzymatic inhibition in the presence of its well known inhibiting drug, proving the suitability of this system for the screening of inhibitors of this enzyme, highly relevant to nicotine addiction treatment. Finally, this molecular engineering approach can aid in the development of improved electrochemical sensors based on CYP enzymes for drug screening and metabolic profiling.

REFERENCES

- (1) Di, Y.M.; Chow, V.D.; Yang, L.P.; Zhou S.F. *Curr. Drug Metab.* **2009**, *10*, 754-780.
- (2) Malaiyandi, V.; Sellers, E.M.; Tyndale, R.F. *Clin. Pharmacol. Ther.* **2005**, *77*, 145-158.
- (3) Benowitz, N.L. *Annu. Rev. Pharmacol. Toxicol.* **2009**, *49*, 57-71.
- (4) Sellers, E.M.; Tyndale, R.F.; Fernandes, L.C. *Drug Discov. Today* **2003**, *8*, 487-493.
- (5) Sellers, E.M.; Kaplan, H.L.; Tyndale, R.F. *Clin. Pharmacol. Ther.* **2000**, *68*, 35-43.
- (6) Hukkanen, J.; Jacob, 3rdP.; Benowitz, N.L. *Clin. Pharmacol. Ther.* **2006**, *80*, 522-530.
- (7) Yano, J.K.; Denton, T.T.; Cerny, M.A.; Zhang, X.; Johnson, E.F.; Cashman, J.R. *J. Med. Chem.* **2006**, *49*, 6987-7001.
- (8) Kontogiorgis, C.; Detsi, A.; Hadjipavlou-Litina, D. *Expert Opin. Ther. Pat.* **2012**, *22*, 437-454.
- (9) Mueller, R.L. *Best Pract. Res. Clin. Haematol.* **2004**, *17*, 23-53.
- (10) Fareed, J.; Thethi, I.; Hoppensteadt, D. *Annu. Rev. Pharmacol. Toxicol.* **2012**, *52*, 79-99.
- (11) Fylaktakidou, K.C.; Hadjipavlou-Litina, D.J.; Litinas, K.E.; Nicolaides, D.N. *Curr. Pharm. Des.* **2004**, *10*, 3813-3833.
- (12) Epifano, F.; Curini, M.; Menghini, L.; Genovese S. *Mini Rev. Med. Chem.* **2009**, *9*, 1262-1271.
- (13) Anand, P.; Singh, B.; Singh, N. *Bioorg. Med. Chem.* **2012**, *20*, 1175-1180.

- (14) Singh, I.P.; Bodiwala, H.S. *Nat. Prod. Rep.* **2010**, *27*, 1781-1800.
- (15) Yarman, A.; Wollenberger, U.; Scheller, F.W. *Electrochim. Acta* **2013**, *110*, 63–72.
- (16) Fantuzzi, A.; Capria, E.; Mak, L.H.; Dodhia, V.R.; Sadeghi, S.J.; Collins, S.; Somers, G.; Huq, E.; Gilardi, G. *Anal. Chem.* **2010**, *82*, 10222-10227.
- (17) Schneider, E.; Clark, D.S. *Biosens. Bioelectron.* **2013**, *39*, 1-13.
- (18) Fantuzzi, A.; Fairhead, M.; Gilardi, G. *J. Am. Chem. Soc.* **2004**, *126*, 5040-5041.
- (19) Fantuzzi, A.; Meharena, Y.T.; Briscoe, P.B.; Sassone, C.; Borgia, B.; Gilardi, G. *Chem. Commun. (Camb.)* **2006**, *12*, 1289-1291.
- (20) Dodhia, V.R.; Sassone, C.; Fantuzzi, A.; Di Nardo, G.; Sadeghi, S.J.; Gilardi, G. *Electrochem. Commun.* **2008**, *10*, 1744–1747.
- (21) Ferrero, V.E.V.; Andolfi, L.; Di Nardo, G.; Sadeghi, S.J.; Fantuzzi, A.; Cannistraro, S.; Gilardi, G. *Anal. Chem.* **2008**, *80*, 8438-8446.
- (22) Mak, L.H.; Sadeghi, S.J.; Fantuzzi, A.; Gilardi, G. *Anal. Chem.* **2010**, *82*, 5357-5362.
- (23) Sadeghi, S.J.; Fantuzzi, A.; Gilardi, G. *Biochim. Biophys. Acta* **2011**, *1814*, 237-248.
- (24) Sadeghi, S.J.; Ferrero, S.; Di Nardo, G.; Gilardi, G. *Bioelectrochem.* **2012**, *86*, 87-91.
- (25) Valetti, F.; Sadeghi, S.J.; Meharena, Y.T.; Leliveld, S.R.; Gilardi, G. *Biosens. Bioelectron.* **1998**, *13*, 675-685.
- (26) Sadeghi, S.J.; Meharena, Y.T.; Fantuzzi, A.; Valetti, F.; Gilardi, G. *Faraday Discuss.* **2000**, *116*, 135-153.

- (27) Dodhia, V.R.; Fantuzzi, A.; Gilardi, G. *J. Biol. Inorg. Chem.* **2006**, *11*, 903-916.
- (28) Fairhead, M.; Giannini, S.; Gillam, E.M.; Gilardi, G. *J. Biol. Inorg. Chem.* **2005**, *10*, 842-853.
- (29) Sadeghi, S.J.; Gilardi, G. *Biotech. Appl. Biochem.* **2013**, *60*, 102-110.
- (30) Degregorio, D.; Sadeghi, S.J.; Di Nardo, G.; Gilardi, G.; Solinas, S.P. *J. Biol. Inorg. Chem.* **2011**, *16*, 109-116.
- (31) Laviron E. *J. Electroanal. Chem.* **1979**, *101*, 19-28.
- (32) Yano, J.K.; Hsu, M.H.; Griffin, K.J.; Strout, C.D.; Johnson, E.F. *Nat. Struct. Mol. Biol.* **2005**, *12*, 822-823.
- (33) Castrignanò, S.; Sadeghi, S.J.; Gilardi, G. *Biochim. Biophys. Acta* **2012**, *1820*, 2072-2078.
- (34) Barth A. *Biochim. Biophys. Acta* **2007**, *1767*, 1073-1101.
- (35) Kim, D.; Wu, Z.L.; Guengerich, F.P. *J. Biol. Chem.* **2005**, *280*, 40319-40327.
- (36) Soucek, P. *Arch. Biochem. Biophys.* **1999**, *370*, 190-200.
- (37) He, X.Y.; Shen, J.; Hu, W.Y.; Ding, X.; Lu, A.Y.; Hong, J.Y. *Arch. Biochem. Biophys.* **2004**, *427*, 143-153.
- (38) Fukami, T.; Nakajima, M.; Higashi, E.; Yamanaka, H.; Sakai, H.; McLeod, H.L.; Yokoi, T. *Drug Metab. Dispos.* **2005**, *33*, 1202-1210.

- (39) Yun, C-H; Kim, K-H; Calcutt, M.W.; Guengerich, F.P. *J. Biol. Chem.* 2005, 280, 12279-12291.
- (40) Taavitsainen, P.; Juvonen, R.; Pelkonen, O. *Drug Metab. Dispos.* **2001**, 29, 217-222.
- (41) Zhang, W.; Kilicarslan, T.; Tyndale, R.F.; Sellers, E.M. *Drug Metab. Dispos.* **2001**, 29, 897-902.
- (42) Copeland, R.A. *Enzymes: a practical introduction to structure, mechanism, and data analysis*, 2nd ed.; John Wiley & Sons: New York, 2000.
- (43) Denton, T.T., Zhang, X., Cashman, J.R. *Biochem. Pharmacol.* **2004**, 67, 751-756.
- (44) Murphy, S.E., Raulinaitis, V., Brown, K.M. *Drug Metab. Dispos.* **2005**, 33, 1166-1173.

AUTHOR INFORMATION

Corresponding Author

*G. Gilardi, Department of Life Sciences and Systems Biology, Via Accademia Albertina 13, 10123 Torino, Italy. Phone: +39-011-6704593, Fax: +39-011-6704643, E-mail: gianfranco.gilardi@unito.it

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

ACKNOWLEDGMENT

This work was supported by the Region Piedmont CIPE 2006 (CYP-TECH project, Italy) and Progetto Ateneo 2012 (Torino, Italy).

For TOC only